CLOVER BIO-B(02197) released its annual performance report, with a net loss of 205 million yuan, a year-on-year decrease of 77.3%.
Trifolium Biotech-B (02197) released its annual performance for the year ending December 31, 2025, with a group revenue of 3.505 million yuan, a decrease of 90.88% year-on-year; research and development expenses were 182 million yuan, a decrease of 0.57% year-on-year; net loss was 205 million yuan, a decrease of 77.3% year-on-year.
CLOVER BIO-B (02197) announced its annual performance as of December 31, 2025. The group's revenue was 3.505 million RMB, a decrease of 90.88% compared to the previous year. Research and development expenses were 0.182 billion RMB, a decrease of 0.57% compared to the previous year. The net loss was 2.05 billion RMB, a decrease of 77.3% compared to the previous year.
Related Articles
Sinolink: Escalation of US-Iran conflict reverses "weak US dollar" narrative, strong assets may help reverse market decline and indicate a bottom.
Huachuang Securities: Under the impact of high oil prices in this round, the middle and upper reaches of the profit margin may have more resilience.
Hua Chuang Securities' Zhang Yu: High oil prices bring "clearing out," China's midstream market share may "rise"
Sinolink: Escalation of US-Iran conflict reverses "weak US dollar" narrative, strong assets may help reverse market decline and indicate a bottom.
Huachuang Securities: Under the impact of high oil prices in this round, the middle and upper reaches of the profit margin may have more resilience.
Hua Chuang Securities' Zhang Yu: High oil prices bring "clearing out," China's midstream market share may "rise"
RECOMMEND
Chinese Innovative Drug Assets Attract Major Foreign Acquisition, Cooperation Models Diversify
26/03/2026
Four Giants Subscribe As Memory Manufacturer Confirms TWD 78.718 Billion Private Placement For Capacity Expansion
26/03/2026
Year‑On‑Year Surge Exceeding 500%: Hong Kong IPOs Top HKD 100 Billion This Year
26/03/2026
